Gb Sciences (GBLX)

Overall impact
C (56)

Commentary

Gb Sciences is an average overall performer. With a 'C' rating of 56.3 for overall impact (55th percentile compared to all companies), Gb Sciences ranks 460th out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 456 others, and ahead of Grifols, Jazz Pharmaceuticals, Clearside Biomedical and 122 others. On top material causes for Gb Sciences's industry (Pharmaceuticals & Biotech), Gb Sciences performs well in Reduced Waste (84.2 score), Reduced Use of tobacco (92.5), Sustainable Use of Water (95.2) and 2 other causes where it received an 'A' score and performs poorly in Child and Maternal Health (32.9 score), Improved Mental Health (16.3), Technology Innovation (33.4) and 3 other causes where it received a 'D' or 'F' score.
Impact
Cause GBLX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
2
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Nv, United States
Share classes
GBLX
Description
GB Sciences, Inc. is a plant-based research and biopharmaceutical drug development company. The company offers cannabis-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in the pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress/anxiety/depression, and cardiovascular therapeutic programs. The company was formerly known as Growblox Sciences, Inc. and changed its name to GB Sciences, Inc. in October 2016. GB Sciences, Inc. is based in Las Vegas, Nevada.
Material causes
Ethos considers the following causes material for Gb Sciences, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.